EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC-ND 4.0

Dietary magnesium supplementation in cats with chronic kidney disease: A prospective double-blind randomized controlled trial

Pak-Kan Tang iD, Dirk Hendrik Nicolaas van den Broek iD, Rosanne E Jepson, Rebecca F Geddes iD, Yu-Mei Chang, Nicola Lötter, Delphine Moniot, Vincent Biourge iD, Jonathan Elliott

Journal of Veterinary Internal Medicine · 2024

DOI: 10.1111/jvim.17134 ↗

At a glance

Randomisierte kontrollierte Studie in Journal of Veterinary Internal Medicine, 2024. Written by Pak-Kan Tang and 8 co-authors. Institution: Department of Comparative Biomedical Sciences, Royal Veterinary College, University of London, London, United Kingdom. Major MEDLINE topics: Cat Diseases, Dietary Supplements, Magnesium, Renal Insufficiency, Chronic. Cited 5 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Plasma total magnesium concentration (tMg) is a prognostic indicator in cats with chronic kidney disease (CKD), shorter survival time being associated with hypomagnesemia. Whether this risk factor is modifiable with dietary magnesium supplementation remains unexplored.

Objectives

Evaluate effects of a magnesium-enriched phosphate-restricted diet (PRD) on CKD–mineral bone disorder (CKD-MBD) variables. Animals Sixty euthyroid client-owned cats with azotemic CKD, with 27 and 33 allocated to magnesium-enriched PRD or control PRD, respectively.

Methods

Prospective double-blind, parallel-group randomized trial. Cats with CKD, stabilized on a PRD, without hypermagnesemia (tMg >2.43 mg/dL) or hypercalcemia (plasma ionized calcium concentration, (iCa) >6 mg/dL), were recruited. Both intention-to-treat and per-protocol (eating ≥50% of study diet) analyses were performed; effects of dietary magnesium supplementation on clinicopathological variables were evaluated using linear mixed effects models.

Results

In the per-protocol analysis, tMg increased in cats consuming a magnesium-enriched PRD (β, 0.25 ± .07 mg/dL/month; P < .001). Five magnesium supplemented cats had tMg >2.92 mg/dL, but none experienced adverse effects. Rate of change in iCa differed between groups (P = .01), with decreasing and increasing trends observed in cats fed magnesium-enriched PRD and control PRD, respectively. Four control cats developed ionized hypercalcemia versus none in the magnesium supplemented group. Log-transformed plasma fibroblast growth factor-23 concentration (FGF23) increased significantly in controls (β, 0.14 ± .05 pg/mL/month; P = .01), but remained stable in the magnesium supplemented group (β, 0.05±.06 pg/mL/month; P =.37). Conclusions and Clinical Importance Magnesium-enriched PRD is a novel therapeutic strategy for managing feline CKD-MBD in cats, further stabilizing plasma FGF23 and preventing hypercalcemia.

Subjects

MeSH terms (MEDLINE)

Cat DiseasesDietary SupplementsMagnesiumRenal Insufficiency, ChronicAnimalsCatsFemaleMaleCalciumDietDouble-Blind MethodFibroblast Growth Factor-23PhosphatesProspective Studies

Author keywords

CKD‐MBDanti‐calcemiccalciumfibroblast growth factor‐23hypercalcemiamagnesium oxide

Substances

CalciumFibroblast Growth Factor-23MagnesiumPhosphates

Authors and institutions

  • Department of Comparative Biomedical Sciences, Royal Veterinary College, University of London, London, United Kingdom.
  • Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
  • Department of Clinical Science and Services, Royal Veterinary College, University of London, London, United Kingdom.
  • Research Support Office, Royal Veterinary College, University of London, London, United Kingdom.
  • Royal Canin Research Center, Aimargues, France.

ORCID profiles: Pak-Kan Tang, Dirk Hendrik Nicolaas van den Broek, Rebecca F Geddes, Vincent Biourge

Cite

APA

Tang, P. K., van den Broek, D. H. N., Jepson, R. E., Geddes, R. F., Chang, Y. M., Lötter, N., Moniot, D., Biourge, V., & Elliott, J. (2024). Dietary magnesium supplementation in cats with chronic kidney disease: A prospective double-blind randomized controlled trial. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17134

Vancouver

Tang PK, van den Broek DHN, Jepson RE, Geddes RF, Chang YM, Lötter N, et al. Dietary magnesium supplementation in cats with chronic kidney disease: A prospective double-blind randomized controlled trial. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.17134

BibTeX
@article{Tang2024,
  author = {Tang, Pak-Kan and van den Broek, Dirk Hendrik Nicolaas and Jepson, Rosanne E and Geddes, Rebecca F and Chang, Yu-Mei and Lötter, Nicola and Moniot, Delphine and Biourge, Vincent and Elliott, Jonathan},
  title = {Dietary magnesium supplementation in cats with chronic kidney disease: A prospective double-blind randomized controlled trial},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2024},
  doi = {10.1111/jvim.17134}
}
Start for free →